MoonLake Immunotherapeutics AG
MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa with HiSCR75 as the primary endpoint
Zug, Switzerland (ots/PRNewswire) - - This Phase 2 study represents an important step in hidradenitis suppurativa ("HS") clinical development, as it will be the first to use the higher clinical response level of HiSCR75 as the primary endpoint - Expected to enroll over 200 patients with moderate-to-severe HS to ...
mehr